Martingale Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Martingale Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Sell	38,263 -3,500	-8%	-$33.6K	0.01%	767
2026 Q1	$527K	Buy	41,763 +4,710	+13%	+$54K	0.01%	624
2025 Q4	$381K	Hold	37,053	–	–	0.01%	652
2025 Q3	$215K	Sell	37,053 -2,410	-6%	-$14.1K	0.01%	734
2025 Q2	$265K	Sell	39,463 -700	-2%	-$5.63K	0.01%	723
2025 Q1	$363K	Buy	40,163 +1,540	+4%	+$19.2K	0.01%	651
2024 Q4	$668K	Buy	38,623 +700	+2%	+$12.7K	0.02%	557
2024 Q3	$606K	Buy	37,923 +10,226	+37%	+$161K	0.01%	590
2024 Q2	$395K	Buy	27,697 +9,245	+50%	+$131K	0.01%	651
2024 Q1	$261K	Buy	+18,452	New	+$261K	0.01%	728

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Martingale Asset Management's TRDA Position: Q2 2026 in Review

Martingale Asset Management reduced its Entrada Therapeutics (TRDA) stake by 8.4% in Q2 2026, selling an estimated $33.6K and leaving 38,263 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #767.

Martingale Asset Management first reported a position in TRDA in Q1 2024 and has held it in 10 quarters since. The position peaked at $668K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Martingale Asset Management held 38,263 shares of Entrada Therapeutics worth $282K as of Q2 2026.
Martingale Asset Management sold 3,500 Entrada Therapeutics shares in Q2 2026, an estimated $33.6K.
Entrada Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #767 holding.
Martingale Asset Management first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 10 quarters since.
Martingale Asset Management's Entrada Therapeutics position peaked at $668K in Q4 2024.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.